• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全膝关节或髋关节置换术后的静脉血栓栓塞预防:治疗模式和结果。

Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.

机构信息

PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.

出版信息

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):972-8. doi: 10.1002/pds.2187. Epub 2011 Jul 11.

DOI:10.1002/pds.2187
PMID:21748826
Abstract

PURPOSE

To determine the thromboprophylactic treatment pattern and occurrence of venous thromboembolism (VTE), major bleeding, and wound infections in patients undergoing total knee replacement (TKR) or total hip replacement (THR).

METHODS

From the PHARMO database, all patients ≥ 18 years hospitalized for TKR or THR between January 2003 and September 2008 were selected. Patients with pharmacy data up to 3 months after hospitalization were included in the study cohort. Duration and type of thromboprophylaxis were assessed. VTE, major bleeding, and wound infections were identified by hospitalizations. Regarding VTE, timing of event in relation to thromboprophylaxis was determined.

RESULTS

The study population included 2930 patients with TKR, 5332 patients with THR without hip fracture, and 289 patients with THR and hip fracture. Mean duration of thromboprophylaxis was about 30 (± 20) days for all procedures, with low-molecular-weight heparin being the most frequently used drug. During 3 months of follow-up, 1% to 2% of patients were hospitalized for an event. The most observed event was wound infection (58%), followed by major bleeding (29%), and VTE (13%). For wound infection and major bleeding, median time after surgery was about 19 days. Median time between surgery and VTE was 24 days for TKR and 60 days for THR. Eighteen of 23 VTE occurred during thromboprophylaxis.

CONCLUSIONS

Although patients are often treated for fewer days than recommended, thromboprophylaxis after TKR and THR in the Netherlands is adequate. Only 5 of 23 VTE hospitalizations occurred off-treatment and might have been prevented. Furthermore, fewer than 1% of patients were hospitalized for bleeding.

摘要

目的

确定接受全膝关节置换术(TKR)或全髋关节置换术(THR)的患者的血栓预防治疗模式和静脉血栓栓塞症(VTE)、大出血和伤口感染的发生情况。

方法

从 PHARMO 数据库中,选择 2003 年 1 月至 2008 年 9 月期间因 TKR 或 THR 住院的所有年龄≥18 岁的患者。将在住院后 3 个月内有药房数据的患者纳入研究队列。评估血栓预防的持续时间和类型。通过住院确定 VTE、大出血和伤口感染。关于 VTE,确定事件发生与血栓预防的时间关系。

结果

研究人群包括 2930 例 TKR 患者、5332 例无髋部骨折的 THR 患者和 289 例髋部骨折的 THR 患者。所有手术的平均血栓预防持续时间约为 30(±20)天,低分子肝素是最常用的药物。在 3 个月的随访期间,1%至 2%的患者因事件住院。最常见的事件是伤口感染(58%),其次是大出血(29%)和 VTE(13%)。对于伤口感染和大出血,术后中位数时间约为 19 天。TKR 和 THR 后 VTE 的中位数时间分别为 24 天和 60 天。23 例 VTE 中有 18 例发生在治疗期间。

结论

尽管患者的治疗时间往往短于推荐时间,但荷兰 TKR 和 THR 后的血栓预防是充分的。只有 5 例 VTE 住院发生在停药期间,可能可以预防。此外,不到 1%的患者因出血住院。

相似文献

1
Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.全膝关节或髋关节置换术后的静脉血栓栓塞预防:治疗模式和结果。
Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):972-8. doi: 10.1002/pds.2187. Epub 2011 Jul 11.
2
Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.在管理式医疗人群中,接受全髋关节或全膝关节置换术的患者发生静脉血栓栓塞和出血的风险及费用负担。
J Med Econ. 2011;14(3):324-34. doi: 10.3111/13696998.2011.578698. Epub 2011 Apr 20.
3
Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.抗栓治疗指南对全髋关节和全膝关节置换术后临床结局的影响。
Thromb Res. 2012 Aug;130(2):166-72. doi: 10.1016/j.thromres.2012.01.013. Epub 2012 Feb 23.
4
Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.肾功能损害患者行大型骨科手术后用磺达肝素钠 1.5mg 预防静脉血栓栓塞症:一项真实世界、前瞻性、多中心、队列研究。
Thromb Haemost. 2012 Jun;107(6):1151-60. doi: 10.1160/TH11-09-0640. Epub 2012 Apr 4.
5
The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.研究凝血酶生成机制以及低分子肝素作为全膝关节和髋关节置换术患者的血栓预防作用。
Thromb Res. 2013;132(6):685-91. doi: 10.1016/j.thromres.2013.09.037. Epub 2013 Oct 15.
6
Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.希美加群用于预防择期髋关节或膝关节置换术后静脉血栓栓塞。
Semin Vasc Med. 2005 Aug;5(3):266-75. doi: 10.1055/s-2005-916166.
7
Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.利伐沙班:用于全髋关节或全膝关节置换术后预防静脉血栓栓塞症的研究进展。
Am J Cardiovasc Drugs. 2012 Feb 1;12(1):57-72. doi: 10.2165/11208470-000000000-00000.
8
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.从美国支付者角度看利伐沙班与依诺肝素预防术后静脉血栓栓塞的成本和结局。
J Med Econ. 2011;14(6):824-34. doi: 10.3111/13696998.2011.623203. Epub 2011 Oct 24.
9
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry.全髋关节或膝关节置换术后静脉血栓栓塞预防持续时间与血栓栓塞事件时间进程的比较:全球骨科注册研究结果
J Bone Joint Surg Br. 2007 Jun;89(6):799-807. doi: 10.1302/0301-620X.89B6.18844.
10
In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.住院期间行全髋关节或全膝关节置换术患者的静脉血栓栓塞和出血风险及相关费用。
J Med Econ. 2012;15(4):644-53. doi: 10.3111/13696998.2012.669438. Epub 2012 Mar 12.

引用本文的文献

1
Construction and validation of a predictive model for lower extremity deep vein thrombosis after total knee arthroplasty.构建并验证全膝关节置换术后下肢深静脉血栓形成的预测模型。
Medicine (Baltimore). 2024 Jun 14;103(24):e38517. doi: 10.1097/MD.0000000000038517.
2
Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes.膝关节置换术后患者的静脉血栓栓塞预防:真实世界结局比较。
Int J Clin Pharm. 2021 Jun;43(3):621-628. doi: 10.1007/s11096-020-01173-3. Epub 2020 Oct 18.
3
Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital.
利伐沙班在德国的使用情况:一项关于在医院起始使用的药物的数据库药物利用研究。
Eur J Clin Pharmacol. 2014 Aug;70(8):975-81. doi: 10.1007/s00228-014-1697-7. Epub 2014 May 27.
4
Analysis of disease patterns and cost of treatments for prevention of deep venous thrombosis after total knee or hip replacement: results from the Practice Analysis of THromboprophylaxis after Orthopaedic Surgery (PATHOS) study.全膝关节或髋关节置换术后预防深静脉血栓形成的疾病模式及治疗费用分析:骨科手术后血栓预防实践分析(PATHOS)研究结果
Clinicoecon Outcomes Res. 2013;5:1-7. doi: 10.2147/CEOR.S39978. Epub 2012 Dec 28.